Radioactive microspheres benefit liver met pts

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 6
Volume 17
Issue 6

CHICAGO-Median overall survival was 13 months among 52 patients who received radioactive microspheres (SIR-Spheres) for colorectal cancer liver metastases after chemotherapy failure. The phase II Italian SITILO study was reported at ASCO 2008 (abstract 4078).

CHICAGO-Median overall survival was 13 months among 52 patients who received radioactive microspheres (SIR-Spheres) for colorectal cancer liver metastases after chemotherapy failure. The phase II Italian SITILO study was reported at ASCO 2008 (abstract 4078).

Clinical benefit was seen in 48% (1 CR, 11 PR, 12 SD). In two patients, liver tumors shrank enough to allow potentially curative surgery to be planned. Among the 24 responders, median survival was 16 months vs 8 months for nonresponders (P = .0006); 40% of responders were alive at 2 years vs none of the nonresponders.

“At a minimum, physicians should consider SIR-Spheres for patients who have liver-only or liver-dominant disease and are failing chemotherapy,” said Prof. Maurizio Cosimelli, of the Regina Elena National Cancer Institute, Rome.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Ravi, MD, BChir, MRCP, on the phase 2 LASER trial in RCC.
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
5 experts are featured in this series
4 experts in this video
2 experts are featured in this series.
4 experts in this video
4 experts in this video
4 experts in this video
2 experts are featured in this series.
Related Content